Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era

We reviewed consolidation therapy results and analyzed postremission outcomes for 1464 children less than 21 years old at diagnosis in five consecutive Children's Cancer Group acute myeloid leukemia trials between 1979 and 1996. Children in remission were allocated to allogeneic bone marrow transplantation ( BMT) ( N = 373) in first remission, if a matched family donor was available. Remaining children were assigned consolidation chemotherapy ( N = 688) or autologous purged BMT ( N = 217), or withdrew from study before assignment, or with unknown data ( N = 186). Overall and disease- free survival were superior for children assigned allogeneic transplants. High ( > 50 000/mu l) diagnostic white blood cell ( WBC) count was prognostic for inferior outcome, but French - American - British ( FAB) subtypes were not. Inv( 16) is a favorable karyotypic feature for children in first remission and t( 8; 21) is not. Allogeneic transplantation benefit was evident in most children, including those with high or low diagnostic WBC count, each FAB subtype, and t( 8; 21), but was not seen in children with inv( 16). Therefore, these data suggest reserving matched related donor allogeneic transplantation for children with inv( 16) for second remission, but not those with t( 8; 21).